SEC Form 4 · accession 0001140361-18-000232
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Dec 28, 2017
Accepted (ET)
Jan 2, 2018 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 26, 2017 | G | 430 | $0.00 | D | 226,494 | D | |
| Common StockF2 | Dec 14, 2017 | G | 600 | $0.00 | D | 225,894 | D | |
| Common StockF3 | Dec 28, 2017 | M | 10,000 | $38.59 | A | 235,894 | D | |
| Common StockF3,F4 | Dec 28, 2017 | S | 10,000 | $89.8912 | D | 225,894 | D | |
| Common StockF3 | Dec 29, 2017 | M | 10,000 | $38.59 | A | 235,894 | D | |
| Common StockF3,F6 | Dec 29, 2017 | S | 10,000 | $89.6125 | D | 225,894 | D | |
| Common Stock | holding | — | — | — | 182,801 | I | Shares held by Jean-Jacques Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F3,F5 | $38.59 | Dec 28, 2017 | M | 10,000 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 10,000 | 202,500 | D |
| Stock Option (Right to buy Common Stock)F3,F5 | $38.59 | Dec 29, 2017 | M | 10,000 | D | Nov 22, 2008 | May 21, 2018 | Common Stock | 10,000 | 192,500 | D |
Explanation of responses
- F1On September 26, 2017, the reporting person gifted 430 shares to an educational institution.
- F2On December 14, 2017, the reporting person gifted 600 shares to an educational institution.
- F3Trade made pursuant to a 10b5-1 plan executed on November 14, 2017.
- F4The price in column 4 is the weighted average price. The price actually received ranged from $88.89 to $90.92. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F5Reflects the number of stock options outstanding after the transaction from this specific stock option grant.
- F6The price in column 4 is the weighted average price. The price actually received ranged from $88.97 to $90.45. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.